Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.
暂无分享,去创建一个
L. Dogliotti | E. Testa | A. Berruti | M. Terzolo | G. Osella | A. Angeli | A. Pia | A. Alí | V. Carbone | Anna Alı̀ | V. Carbone | Elio Testa | E. Testa
[1] G. Dickstein. Is There a Role for Low Doses of Mitotane (o,p′,DDD) as Adjuvant Therapy in Adrenocortical Carcinoma?—Authors’ Response , 1999 .
[2] M. Boscaro,et al. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? , 1999, The Journal of clinical endocrinology and metabolism.
[3] L. Dogliotti,et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma , 1998, Cancer.
[4] E. Baudin,et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM. , 1998, British Journal of Cancer.
[5] P. Paccotti,et al. Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas) , 1994, The Journal of clinical endocrinology and metabolism.
[6] P. Trainer,et al. Cushing's syndrome. Therapy directed at the adrenal glands. , 1994, Endocrinology and metabolism clinics of North America.
[7] G. Fleuren,et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. , 1994, British Journal of Cancer.
[8] M. Wooten,et al. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature , 1993, Cancer.
[9] M. Brennan,et al. An eleven-year experience with adrenocortical carcinoma. , 1992, Surgery.
[10] G. Thompson,et al. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia. , 1992, The Quarterly journal of medicine.
[11] A. Moolenaar,et al. Mitotane increases the blood levels of hormone-binding proteins. , 1991, Acta endocrinologica.
[12] P Blondeau,et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. , 1990, The New England journal of medicine.
[13] N. Samaan,et al. Adrenal cortical carcinoma , 1989, Cancer.
[14] A. Henniker,et al. THE EFFECT OF o,p'‐DDD ON ADRENAL STEROID REPLACEMENT THERAPY REQUIREMENTS , 1987, Clinical endocrinology.
[15] R. D. de Zeeuw,et al. Rapid micromethod for the analysis of mitotane and its metabolite in plasma by gas chromatography with electron-capture detection. , 1987, Journal of chromatography.
[16] E Boven,et al. Complete response of metastasized adrenal cortical carcinoma with o,p'‐ddd.Case report and literature review , 1984, Cancer.
[17] H. V. van Slooten,et al. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. , 1984, European journal of cancer & clinical oncology.
[18] N. Thompson,et al. Treatment of adrenal carcinomas. , 1982, Archives of surgery.
[19] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .
[20] L. Freeman,et al. Mitotane use in inoperable adrenal cortical carcinoma. , 1973, JAMA.
[21] D. L. Hoffman,et al. Treatment of adrenocortical carcinoma with o,p'-DDD. , 1972, The Medical clinics of North America.
[22] Moy Rh. Studies of the pharmacology of o,p'DDD in man. , 1961 .